AtriCure (ATRC) Stock Price, News & Analysis

Company Overview

AtriCure, Inc. is a medical technology company focused on the treatment of atrial fibrillation (AF) and related left atrial appendage management. The company designs, develops, manufactures and markets surgical ablation devices, adjunctive products and diagnostic tools that support the safe and effective treatment of AF. AtriCure’s product portfolio includes bipolar clamp-based and irrigated radiofrequency ablation systems, cryoablation tools, and a range of stapling and clipping devices intended for left atrial appendage occlusion.

Since its founding in 2000 and subsequent initial public offering in 2005, AtriCure has been committed to advancing the field of surgical electrophysiology through continuous innovation and clinical collaboration. Early investments in research and development led to its signature Isolator Synergy™ Clamp and EPi-Sense® System, which were among the first FDA-cleared devices for surgical AF ablation. Over the years, the company has expanded its technology base by acquiring complementary assets, strengthening its portfolio with products such as cryoICE® cryoablation probes and fabric-encased left atrial appendage occlusion devices.

AtriCure maintains a global commercial footprint, marketing its products in more than 50 countries across North America, Europe, Asia Pacific and Latin America. The company’s U.S. headquarters and primary manufacturing facility are located in Mason, Ohio, with additional sales and support operations in Europe and Asia. AtriCure conducts ongoing clinical studies and collaborates with leading cardiac surgeons and electrophysiologists to validate new techniques and expand the adoption of surgical AF ablation in both stand-alone and hybrid operating room settings.

Leadership at AtriCure is led by President and Chief Executive Officer Michael J. Carrel, who has guided the company’s strategic growth and product development initiatives. Under his stewardship, AtriCure has focused on expanding education programs for clinicians, forging partnerships with healthcare systems and enhancing its post-market surveillance capabilities. The company continues to invest in innovation aimed at improving patient outcomes in AF treatment and strengthening its position within the global cardiac surgery market.

Key Stats

• Today's Range: $31.26 to $31.90
• 50-Day Range: $29.07 to $34.94
• 52-Week Range: $20.20 to $43.11
• Volume: 153,425 shs
• Average Volume: 603,779 shs
• Market Capitalization: $1.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.67
• Consensus Rating: Buy

AtriCure Stock Analysis - MarketRank™

AtriCure scored higher than 65% of companies evaluated by MarketBeat, and ranked 334th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AtriCure has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AtriCure is -38.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AtriCure is -38.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AtriCure has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.27% of the float of AtriCure has been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AtriCure has recently decreased by 14.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AtriCure does not currently pay a dividend.

Dividend Growth

AtriCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.27% of the float of AtriCure has been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AtriCure has recently decreased by 14.75%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.26

News Sentiment

AtriCure has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for AtriCure this week, compared to 5 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,600.00 in company stock.

Percentage Held by Insiders

Only 3.50% of the stock of AtriCure is held by insiders.

Percentage Held by Institutions

99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRC Stock Analysis - Frequently Asked Questions

How have ATRC shares performed this year?

AtriCure's stock was trading at $30.56 at the start of the year. Since then, ATRC shares have increased by 3.2% and is now trading at $31.53.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Tuesday, April, 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.11. The firm's quarterly revenue was up 13.5% on a year-over-year basis.
Read the conference call transcript.

Does AtriCure have any subsidiaries?

AtriCure subsidiaries include these companies: SentreHEART.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ATRC
• CIK: 1323885
• Web: www.atricure.com
• Phone: (513) 755-4100
• Fax: 513-755-4567
• Employees: 1,300
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $50.67
• High Stock Price Target: $60.00
• Low Stock Price Target: $44.00
• Potential Upside/Downside: +59.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.70 million
• Net Margins: -7.95%
• Pretax Margin: -7.73%
• Return on Equity: -5.68%
• Return on Assets: -4.34%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 4.11
• Quick Ratio: 2.88

Sales & Book Value

• Annual Sales: $465.31 million
• Price / Sales: 3.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 3.36

Miscellaneous

• Outstanding Shares: 49,510,000
• Free Float: 47,772,000
• Market Cap: $1.57 billion
• Optionable: Optionable
• Beta: 1.56